Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: UnivDatos Market Insights Pvt Ltd | PRODUCT CODE: 1324889

Cover Image

PUBLISHER: UnivDatos Market Insights Pvt Ltd | PRODUCT CODE: 1324889

Loratadine Syrup Market: Current Analysis and Forecast (2022-2030)

PUBLISHED:
PAGES: 158 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 3999
PDF (Site License)
USD 5499
PDF (Global License)
USD 6999

Add to Cart

Loratadine syrup is a medication used to provide relief from allergy symptoms. This is known for its non-drowsy formula, making it suitable for daytime use without causing significant sedation. It effectively alleviates symptoms like sneezing, runny nose, itching, and watery eyes associated with allergies, providing long-lasting relief. The syrup formulation offers convenience, particularly for pediatric populations or individuals who have difficulty swallowing pills, as it allows for easy administration and accurate dosing. The loratadine syrup market is experiencing steady growth and is driven by several key factors such as the increasing prevalence of allergies, such as seasonal allergies, hay fever, and allergic rhinitis, which has fueled the demand for loratadine syrup. For instance, according to an article published by a U.S. organization, 339 million are suffering from asthma, 200 to 250 million have a food allergy and 400 million have rhinitis globally.

The loratadine syrup market is expected to grow at a steady rate of around 2% owing to Its over-the-counter availability, favorable safety profile, and non-drowsy formula making it a preferred choice for consumers across different age groups. Moreover, the growing awareness about allergies and their impact on health, coupled with the urbanization and environmental factors contributing to allergen exposure, has bolstered the market demand for loratadine syrup.

Based on age, the market is segmented into adult and pediatric. The pediatric category is to witness a higher CAGR during the forecast period. This is mainly due to the high prevalence of allergies and hay fever in children, consider a safe medication for children and long-acting formulations. For instance, in 2021, around 81 million people in the U.S. were diagnosed with seasonal allergic rhinitis (hay fever). This equals around 26% (67 million) of adults and 19% (14 million) of children.

On the basis of indication, the market is categorized into allergic rhinitis and urticaria. Among these, allergic rhinitis held a significant share of the market in 2021. This is mainly due to the growing investment & funding activities by government bodies and the rising prevalence of allergic rhinitis all over the world. For instance, as per the National Institutes of Health (NIH), around 339 million are suffering from asthma, 200 to 250 million have a food allergy and 400 million have rhinitis globally.

Based on drug type, the loratadine syrup market has been classified into branded and generic. The branded category is to witness higher adoption of loratadine syrup during the forecast period. This is mainly due to the pharmaceutical companies spending on marketing & branding and their loyalty being higher. Also, brand-name pills are usually the first version of the drug on the market, and this specific version has undergone careful testing to ensure efficacy to consumers.

For a better understanding of the market adoption of the loratadine syrup industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. the large population, coupled with increasing urbanization and industrialization, has led to a rise in allergy cases in the region. APAC also experiences a higher prevalence of allergic rhinitis due to environmental factors. For instance, as per an article published by the National Library of Medicine (NLM), with more than 1.35 billion people, India is home to nearly 20% of the global population. Of all chronic diseases, allergic diseases such as allergic rhinitis (AR) and asthma seem to increase in India over the past few years. Approximately, 22% of adults at present experience allergic rhinitis (AR) in the region. As a result, there is an increasing demand for effective allergy relief medications like loratadine syrup. The growing middle class, rising healthcare expenditure, and improving healthcare infrastructure in countries like China, India, and Japan contribute to the market growth. Additionally, the availability of loratadine syrup as an OTC medication in several countries within the APAC region makes it easily accessible to consumers.

Some of the major players operating in the market include: Merck KGaA; Cadila Pharmaceuticals; Medico Remedies Limited; Sun Pharmaceutical Industries Ltd.; GSK plc.; Perrigo Company plc; Novartis AG; Taro Pharmaceutical Industries Ltd.; Dr. Reddy's Laboratories Ltd.; and Bayer Inc.

Product Code: UMHE211921

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Loratadine Syrup Market
  • 2.2. Research Methodology of the Loratadine Syrup Market
  • 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE LORATADINE SYRUP MARKET

6 LORATADINE SYRUP MARKET REVENUE, 2020-2030F

7 MARKET INSIGHTS BY AGE

  • 7.1. Adult
  • 7.2. Pediatric

8 MARKET INSIGHTS BY INDICATION

  • 8.1. Allergic Rhinitis
  • 8.2. Urticaria

9 MARKET INSIGHTS BY DRUG TYPE

  • 9.1. Branded
  • 9.2. Generic

10 MARKET INSIGHTS BY REGION

  • 10.1. North America
    • 10.1.1. U.S.
    • 10.1.2. Canada
    • 10.1.3. Rest of North America
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. U.K.
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Rest of Asia-Pacific
  • 10.4. Rest of World

11 LORATADINE SYRUP MARKET DYNAMICS

  • 11.1. Market Drivers
  • 11.2. Market Challenges
  • 11.3. Impact Analysis

12 LORATADINE SYRUP MARKET OPPORTUNITIES

13 LORATADINE SYRUP MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

  • 14.1. Demand Side Analysis
  • 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 PRICING ANALYSIS

17 STRATEGIC INSIGHTS

18 COMPETITIVE SCENARIO

  • 18.1. Competitive Landscape
    • 18.1.1. Porters Fiver Forces Analysis

19 COMPANY PROFILED

  • 19.1. Merck KGaA
  • 19.2. Cadila Pharmaceuticals
  • 19.3. Medico Remedies Limited
  • 19.4. Sun Pharmaceutical Industries Ltd.
  • 19.5. GSK plc.
  • 19.6. Perrigo Company plc,
  • 19.7. Novartis AG
  • 19.8. Taro Pharmaceutical Industries Ltd.
  • 19.9. Dr. Reddy's Laboratories Ltd.
  • 19.10. Bayer Inc.

20 DISCLAIMER

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!